Novo Nordisk and ZymoGenetics has announced an agreement where Novo Nordisk in-licenses a fully-human anti-IL21 monoclonal antibody (IL-21 mAb) developed by ZymoGenetics, and broad intellectual property rights covering
Actelion has decided to proceed with advanced clinical development with its orally available and selective S1P1 receptor agonist (ACT-128800) in psoriasis. ACT-128800 is already in advanced clinical development
Neovacs has initiated Phase IIa clinical study of its TNFa Kinoid immunotherapy in rheumatoid arthritis patients who have ceased to respond to an anti-TNFa monoclonal antibody and who
Galapagos has initiated clinical Phase I development of the first small molecule candidate from its arthritis alliance with GlaxoSmithKline (GSK). For entering the clinic with candidate drug GLPG0555,
ImmunoGen has presented positive initial clinical findings with SAR3419 at the American Society of Hematology (ASH) 51st Annual Meeting and Exposition. Among the findings reported were responses to
BD Diagnostics, a segment of BD (Becton, Dickinson and Company) has received clearance from the FDA to utilise its BD ProbeTec Chlamydia trachomatis (CT) Qx and BD ProbeTec
Interleukin Genetics has received approval from the state of New York’s Department of Health, to sell in New York its PST genetic test that determines predisposition to severe
Eli Lilly and Company (Lilly) has announced the availability of a first smaller insulin vial in the US, containing 3ml (300 units) of insulin, for people with diabetes
Roche has reported that the pivotal phase III study, CLL8 showed that patients with previously-untreated chronic lymphocytic leukemia (CLL) survived their disease longer when treated with MabThera/Rituxan (rituximab),
Medicilon/MPI Preclinical Research-Shanghai has recently expanded their service offerings to provide Sponsors with the ability to conduct studies that meet the FDA’s Good Laboratory Practice (GLP) regulations, at
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.